Figure 4.
External validation of the ALFA decision tool. OS according to ALFA decision tiers: (A) 141 patients accrued to the Hauts-De-France registry (HDF cohort); (B) 466 patients accrued to Study Alliance Leukemia trials (SAL cohort); and (C) 233 patients ≥60 years or older excluding t(15;17) cases in the AML Study Group public dataset7,29 (AMLSG cohort). Characteristics of these cohorts are provided in supplemental Table 3. P values from log-rank tests.

External validation of the ALFA decision tool. OS according to ALFA decision tiers: (A) 141 patients accrued to the Hauts-De-France registry (HDF cohort); (B) 466 patients accrued to Study Alliance Leukemia trials (SAL cohort); and (C) 233 patients ≥60 years or older excluding t(15;17) cases in the AML Study Group public dataset7,29  (AMLSG cohort). Characteristics of these cohorts are provided in supplemental Table 3. P values from log-rank tests.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal